Related Experiment Video
Updated: Jan 7, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
Sublingual Cyclobenzaprine: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com.
Sublingual cyclobenzaprine, a novel formulation for fibromyalgia, has been approved in the USA. This rapid-absorption drug offers a new bedtime treatment option for patients with this chronic pain condition.
Area of Science:
- Pharmacology
- Drug Development
- Neurology
Background:
- Fibromyalgia is a chronic condition characterized by widespread pain and tenderness.
- Current treatments for fibromyalgia have limitations in efficacy and tolerability.
- Tonix Pharmaceuticals developed TONMYA™, a sublingual cyclobenzaprine formulation.
Purpose of the Study:
- To summarize the development milestones of sublingual cyclobenzaprine.
- To highlight the regulatory approval for fibromyalgia treatment.
- To introduce a novel therapeutic option for fibromyalgia.
Main Methods:
- Review of development data for sublingual cyclobenzaprine.
- Analysis of pharmacokinetic properties for rapid transmucosal absorption.
- Summary of regulatory submission and approval process.
Main Results:
- Sublingual cyclobenzaprine demonstrated rapid absorption and suitable pharmacokinetic profile for bedtime use.
- The formulation was approved by the US FDA on August 15, 2025, for fibromyalgia.
- This approval marks the first indication for this novel drug formulation.
Conclusions:
- Sublingual cyclobenzaprine represents a significant advancement in fibromyalgia treatment.
- The unique formulation allows for diurnal variation in drug concentration, optimizing bedtime administration.
- This approval offers a new therapeutic avenue for patients suffering from fibromyalgia.
More Related Videos
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
07:54Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Related Concept Videos
Drug Delivery: Enteral Route
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Cholinergic Antagonists: Pharmacokinetics
Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal Muscle Relaxants: Adverse Effects
Unlike...